A recent research study, conducted by Shi and colleagues and published in the Clinical Journal of the American Society of Nephrology, highlighted compelling evidence that endothelin receptor antagonists (ERAs) offer substantial therapeutic benefits for patients with chronic kidney disease (CKD) while clarifying their safety profile, particularly regarding fluid retention concerns. The meta-analysis strengthens the commercial case for broader ERA indication expansion beyond immunoglobulin A (IgA) nephropathy into diabetic kidney disease, says GlobalData, a leading intelligence and productivity platform.
The analysis validates ERAs as disease-modifying agents in CKD, offering clinically relevant benefits that extend beyond symptomatic proteinuria reduction to meaningful hard endpoints like end-stage kidney disease (ESKD) prevention.
Conducted by researchers at Beijing Anzhen Hospital, the study represents the most comprehensive synthesis to date on ERA efficacy and safety in CKD populations. ERAs exhibited substantial nephroprotective effects, reducing ESKD risk by 24% (risk ratio [RR]=0.76, 95% confidence interval [CI] 0.61–0.96). The antiproteinuric effects proved particularly promising, with marked reductions in both urine protein-to-creatinine ratio and urine albumin-to-creatinine ratio.
Kajal Jaddoo, Senior Pharma Analyst at GlobalData, comments: “As the meta-analysis demonstrated that ERAs do not significantly increase edema or heart failure incidence despite modest brain natriuretic peptide elevation and weight gain, the study provides critical safety reassurance for clinical adoption.”
According to GlobalData’s Drugs Database, seven ERAs are currently in active development for chronic kidney disease and diabetic nephropathy.
Jaddoo concludes: “The successful integration of ERAs into clinical practice will depend on overcoming implementation inertia through primary care engagement, and demonstration of additive benefit when layered onto established four-pillar therapy in ongoing combination trials.”
